

Biostar Pharmaceuticals, Inc.  
Form 8-K  
October 25, 2010

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 25, 2010

BIOSTAR PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in Charter)

|  |                       |                                      |
|--|-----------------------|--------------------------------------|
| Maryland   | 001-34708             | 20-8747899                           |
| (State or other jurisdiction of<br>incorporation or<br>organization) | (Commission File No.) | (IRS Employer Identification<br>No.) |

No. 588 Shiji Avenue  
Xiangyang City, Shaanxi Province  
People's Republic of China 712046  
(Address of Principal Executive Offices)

86-029-33686638]  
(Issuer Telephone Number)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01

Other Events.

On October 25, 2010, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1, and the information in Exhibit 99.1 is incorporated herein by reference.

The information in Item 8.01 and Item 9.01(d) in this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit

| Number | Description                                 |
|--------|---|
| 99.1   | <u>Press Release dated October 25, 2010</u> |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 25, 2010

Biostar Pharmaceuticals, Inc.  
(Registrant)

By: /s/ Deyin Chen  
Deyin Chen  
Chief Financial Officer